NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo
| Status: | Terminated |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 25 - 76 |
| Updated: | 4/21/2016 |
| Start Date: | August 2010 |
| End Date: | December 2015 |
NIR (Near Infrared Spectral Tomography)Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo.
The purpose of this study is to determine whether an experimental alternative imaging
method, Near Infrared Spectroscopy (abbreviated as NIR), can be used with a controlled
respiratory system to examine the breasts for cancer. The NIR system uses light beams to
produce an image or picture of the inside of the breast. The respiratory system will help
researchers get more information about the breast tissue by changing the amount of oxygen
the tissue receives during NIR imaging.
method, Near Infrared Spectroscopy (abbreviated as NIR), can be used with a controlled
respiratory system to examine the breasts for cancer. The NIR system uses light beams to
produce an image or picture of the inside of the breast. The respiratory system will help
researchers get more information about the breast tissue by changing the amount of oxygen
the tissue receives during NIR imaging.
Inclusion Criteria:
- NORMAL cohort
1. Breast size and epithelial integrity adequate to allow NIR imaging exams
2. No serious associated psychiatric illnesses
3. Female, ≥25 and <76 years old
4. Written informed consent
- UNDER TREATMENT cohort
1. Locally advanced breast cancer, with or without metastatic disease, defined as
being clinically appropriate for neoadjuvant therapy
2. Breast size and epithelial integrity adequate to allow NIR imaging exams
3. No serious associated psychiatric illnesses
4. Female, ≥25 and <76 years old
5. Written informed consent
Exclusion Criteria:
- both cohorts
1. Pre-existing respiratory conditions:
1. severe chronic obstructive pulmonary disease (including chronic bronchitis
and/or emphysema)
2. Other respiratory or lung conditions which would place the patient at risk
3. presence of any other significant cardiac or pulmonary symptoms, such as
moderate or severe dyspnea on exertion, orthopnea, or paroxysmal nocturnal
dyspnea
2. Congestive heart failure
3. Intolerance of hyperoxia or hypercarbia as delivered by the RespirAct breathing
circuit
4. Pregnancy
We found this trial at
1
site
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
